2. Search Result
Search Result
Results for "

degradation activity

" in MedChemExpress (MCE) Product Catalog:

589

Inhibitors & Agonists

3

Screening Libraries

2

Fluorescent Dye

7

Biochemical Assay Reagents

18

Peptides

2

Inhibitory Antibodies

49

Natural
Products

12

Isotope-Labeled Compounds

7

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112057
    Pseudoerythromycin A enol ether

    LY267108

    		 Drug Metabolite Others
    Pseudoerythromycin A enol ether (LY267108) is a degradation product of Erythromycin. Pseudoerythromycin A enol ether has no significant antimicrobial activity .
    Pseudoerythromycin A enol ether
  • HY-157164
    PROTAC EZH2 Degrader-2
    1 Publications Verification

    		 PROTACs Histone Methyltransferase Apoptosis Cancer
    PROTAC EZH2 Degrader-2 is a PROTAC EZH2 inhibitor. PROTAC EZH2 Degrader-2 degrades EZH2 in SU-DHL-6 cells in a dose-dependent manner. PROTAC EZH2 Degrader-2 induces apoptosis and reduces mitochondrial membrane potential in SU-DHL-6 cells. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity. (Pink: EZH2 ligand (HY-15335), Blue: MDM2 Ligand (HY-147230), Black: Linker (HY-175707), EZH2 ligand-linker conjugate (HY-175706)) .
    PROTAC EZH2 Degrader-2
  • HY-152154
    Nampt degrader-2

    		PROTACs NAMPT Cancer
    Nampt degrader-2 is a fluorescent PROTAC, which efficiently degrades NAMPT with an IC50 of 41.9 nM. Nampt degrader-2 binds to NAMPT and VHL to form a ternary complex and subsequently induced NAMPT degradation via ubiquitin-proteasome system (UPS). Nampt degrader-2 leads to significant reduction of NAD + and exerts potent antitumor activities .
    Nampt degrader-2
  • HY-147525
    PROTAC EZH2 Degrader-1
    1 Publications Verification

    		 PROTACs Histone Methyltransferase Cancer
    PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC50 of 2.7 nM. EZH2 plays an important role in many tumorigenesis and development processes .
    PROTAC EZH2 Degrader-1
  • HY-128756
    SIAIS178

    		PROTACs Bcr-Abl Cancer
    SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity .
    SIAIS178
  • HY-148061
    DB1113

    		PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Others
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
    DB1113
  • HY-148062
    RSS0680

    		PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 Others
    RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC with protein kinase degradation activity (Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078)). RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].
    RSS0680
  • HY-156244
    PROTAC GDI2 Degrader-1

    		PROTACs Cancer
    PROTAC GDI2 Degrader-1 (compound 21) is a potent PROTAC GDI2 degrader. PROTAC GDI2 Degrader-1 exhibits excellent in vivo antitumor activity in the GDI2-overexpressing pancreatic xenograft models .
    PROTAC GDI2 Degrader-1
  • HY-125564
    Acetyltrialanine

    		Aminopeptidase Others
    Acetyltrialanine is a peptide containing three amino acid residues in which the N-terminal amino acid is acetylated and used as a substrate for Nα-acetyl alanine aminopeptidase in order to study the activity and properties of the enzyme. Acetyltrialanine can be used in the study of protein degradation and N-terminal regulation .
    Acetyltrialanine
  • HY-178964
    PROTAC RET Degrader 1

    		PROTACs RET Cancer
    PROTAC RET Degrader 1 (Compound 20) is an orally active and blood-brain barrier-crossing RET PROTAC degrader with DC50 values for RET (WT), RET (G810S), RET (G810C), and RET (G810R) of 1.7, 3, 12, and 21 nM, respectively. PROTAC RET Degrader 1 exhibits potent anti-proliferative activity in cancer cell lines carrying oncogenic RET fusions (such as KIF5B-RET, CCDC6-RET) or mutations (such as RET (C634W)). PROTAC RET Degrader 1 shows significant anti-tumor activity in human tumor xenograft (PDX) mouse models. PROTAC RET Degrader 1 can be used for the study of RET-positive cancers Pink: RET ligand (HY-179308); Blue: CRBN ligand (HY-179307); Black: Linker) .
    PROTAC RET Degrader 1
  • HY-164487
    JBJ-08-178-01

    		Proteasome Cancer
    JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .
    JBJ-08-178-01
  • HY-157213
    LWY713

    		Apoptosis PROTACs FLT3 Cancer
    LWY713 is a PROTAC-class FLT3 degrader (DC50=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).
    LWY713
  • HY-178862
    CDK9 ligand-Linker Conjugate

    		Target Protein Ligand-Linker Conjugates Cancer
    CDK9 ligand-Linker Conjugate is a synthesized CDK9 ligand-linker conjugate that can be used for synthesis of dCDK9-202 (HY-178861). dCDK9-202 is a potent CDK9 PROTAC degrader with anti-tumor activity .
    CDK9 ligand-Linker Conjugate
  • HY-162764
    Androgen receptor degrader-5

    		Androgen Receptor Cancer
    Androgen receptor degrader-5 (compound 14k) exhibits promising properties, including superior androgen receptor degradation activity and antiproliferative activity .
    Androgen receptor degrader-5
  • HY-153674
    PROTAC SOS1 degrader-4

    		SOS1 PROTACs Ras Cancer
    PROTAC SOS1 degrader-4 (compound 10) is a potent SOS1 degrader. PROTAC SOS1 degrader-4 shows antiproliferative activity .
    PROTAC SOS1 degrader-4
  • HY-173327
    BRD4 degrader-6

    		PROTACs Epigenetic Reader Domain Cancer
    BRD4 degrader-6 is a dimeric BDR4 PROTAC degrader (DC50: < 0.1 μM). BRD4 degrader-6 promotes the ubiquitination and degradation of BDR4 and has anticancer activity .
    BRD4 degrader-6
  • HY-144624
    PROTAC Axl Degrader 1

    		PROTACs TAM Receptor Cancer
    PROTAC Axl Degrader 1 is a potent and selective PROTAC Axl degrader with an IC50 of 0.92 μM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces mehuosis .
    PROTAC Axl Degrader 1
  • HY-144627
    PROTAC Axl Degrader 2

    		PROTACs TAM Receptor Cancer
    PROTAC Axl Degrader 2 is a potent and selective PROTAC Axl degrader with an IC50 of 1.61 μM. PROTAC Axl Degrader 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 2 induces mehuosis .
    PROTAC Axl Degrader 2
  • HY-144304
    PROTAC EGFR degrader 2

    		PROTACs EGFR Cancer
    PROTAC EGFR degrader 2 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC50 of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM. PROTAC EGFR degrader 2 can be used for the synthesis of nitroreductase (NTR)-responsive PROTAC .
    PROTAC EGFR degrader 2
  • HY-160533
    IKZF1-degrader-2

    		Molecular Glues IKZF Family Cancer
    IKZF1-degrader-2 (Compound 3) is an IKZF1 molecular glues degrader. IKZF1-degrader-2 has anticancer activity and low toxicity .
    IKZF1-degrader-2
  • HY-149969
    ER degrader 4

    		Estrogen Receptor/ERR Cancer
    ER degrader 4 is a selective and orally active estrogen receptor degrader. ER degrader 4 has anti-tumor activity .
    ER degrader 4
  • HY-147654
    PROTAC Hemagglutinin Degrader-1

    		PROTACs Influenza Virus Infection
    PROTAC Hemagglutinin Degrader-1 (Compound V3) is a potent PROTAC influenza hemagglutinin (HA) degrader with a median degradation concentration of 1.44 μM. PROTAC Hemagglutinin Degrader-1 shows broad-spectrum anti-influenza virus activity .
    PROTAC Hemagglutinin Degrader-1
  • HY-130850
    CDK9-IN-10

    		CDK Ligands for Target Protein for PROTAC Cancer
    CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .
    CDK9-IN-10
  • HY-149970
    ER degrader 5

    		Estrogen Receptor/ERR Cancer
    ER degrader 5 is a potent estrogen receptor (ER) degrader. ER degrader 5 shows anti-proliferation activity. ER degrader 5 can be used for the research of breast cancer .
    ER degrader 5
  • HY-168530
    PDL1 degrader-1

    		PD-1/PD-L1 Cancer
    PDL1 degrader-1 (compound PMT-O9-1A) is a potent PD-L1 degrader. PDL1 degrader-1 decreases the protein expression of PD-L1. PDL1 degrader-1 shows cytotoxicity. PDL1 degrader-1 shows anticancer activity .
    PDL1 degrader-1
  • HY-169278
    PROTAC SMARCA2 degrader-26

    		Epigenetic Reader Domain PROTACs Cancer
    PROTAC SMARCA2 degrader-26 (compound 45) is a potent SMARCA2 PROTAC degrader. PROTAC SMARCA2 degrader-26 induces SMARCA2 and SMARCA4 degradation in VCaP cells with the percent degradation of 94% and 57% for SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2 degrader-26 shows antiproliferative activity .
    PROTAC SMARCA2 degrader-26
  • HY-178861
    dCDK9-202

    		PROTACs CDK Caspase PARP Apoptosis Cancer
    dCDK9-202 a potent CDK9 PROTAC degrader with an DC50 value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862); Blue: CRBN ligand (HY-W248665); Black: Linker (HY-N8015)) .
    dCDK9-202
  • HY-145737
    PROTAC SOS1 degrader-1

    		PROTACs Ras Cancer
    PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .
    PROTAC SOS1 degrader-1
  • HY-157216
    HDAC1 Degrader-1

    		HDAC Cancer
    HDAC1 Degrader-1 (compound 1a) is an HDAC1 degrader with anticancer activity. HDAC1 Degrader-1 significantly reduces HDAC1 levels in MM.1S multiple myeloma cells .
    HDAC1 Degrader-1
  • HY-170495
    HDAC6 degrader-5

    		HDAC Apoptosis Interleukin Related Inflammation/Immunology
    HDAC6 degrader-5 (Compound 6) exhibits inhibitory and degradation activity against HDAC6, with an IC50 of 4.95 nM and a DC50 of 0.96 nM. HDAC6 degrader-5 inhibits the release of TNF-α, IL-1β and IL-6, blocks the hepatocyte apoptosis. HDAC6 degrader-5 exhibits anti-inflammatory activity in mouse APAP (HY-66005)-induced liver injury models .
    HDAC6 degrader-5
  • HY-144605
    PROTAC EGFR degrader 3

    		EGFR PROTACs Cancer
    PROTAC EGFR degrader 3 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation .
    PROTAC EGFR degrader 3
  • HY-173320
    HEMTAC WEE1 degrader-1

    		Wee1 HSP Cancer
    HEMTAC WEE1 degrader-1 is a HSP90-mediated targeting chimera (HEMTAC) degrader of WEE1 (HSP90 enzyme inhibitory activity is IC50: 16.76 nM). HEMTAC WEE1 degrader-1 promotes the ubiquitination and degradation of WEE1. HEMTAC WEE1 degrader-1 blocks the G2/M cell cycle. HEMTAC WEE1 degrader-1 has anticancer activity in acute myeloid leukemia (AML) patient-derived xenograft (PDX) models. HEMTAC WEE1 degrader-1 can be used in AML research. (Pink: HSP90 binder; Blue: WEE1 ligand; Black: linker) .
    HEMTAC WEE1 degrader-1
  • HY-145737A
    PROTAC SOS1 degrader-1 TFA

    		PROTACs Ras Cancer
    PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC50 of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .
    PROTAC SOS1 degrader-1 TFA
  • HY-153415
    PROTAC BCR-ABL Degrader-1

    		PROTACs Bcr-Abl Cancer
    PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoethyl linker. PROTAC BCR-ABL Degrader-1 induces Bcr-Abl degradation in a ubiquitinproteasom-dependent manner. PROTAC BCR-ABL Degrader-1 exhibits antiproliferative activity against K562 cells, and has the potential to study cancer .
    PROTAC BCR-ABL Degrader-1
  • HY-172882
    IKZF2-degrader 1

    		Molecular Glues IKZF Family Cancer
    IKZF2-degrader 1 (Compound 31) is a IKZF2 molecular glue degrader, with an DC50 of 0.5 nM. IKZF2-degrader 1 has minimal CK1α degradation activity relatively (DC50: 210 nM). IKZF2-degrader 1 can be used for research of IKZF2-dependent cancers .
    IKZF2-degrader 1
  • HY-164827
    CDK2 degrader 3

    		CDK Cancer
    CDK2 degrader 3 can selectively degrade CDK2 and has anti-tumor activity .
    CDK2 degrader 3
  • HY-178831
    Azacyclohexane-C-piperazine-C(OCH3)2

    		PROTAC Linkers Neurological Disease
    Azacyclohexane-C-piperazine-C(OCH3)2 is a PROTAC linker that can be used to synthesize PROTAC LRRK2 Degrader-4 (HY-178796). PROTAC LRRK2 Degrader-4 is a potent LRRK2 PROTAC degrader with anti-neuroinflammatory activity .
    Azacyclohexane-C-piperazine-C(OCH3)2
  • HY-178830
    Azacyclohexane-O-cyclohexane-C-(OCH3)2

    		PROTAC Linkers Neurological Disease
    Azacyclohexane-O-cyclohexane-C-(OCH3)2 is a PROTAC linker that can be used to synthesize PROTAC LRRK2 Degrader-3 (HY-178797). PROTAC LRRK2 Degrader-3 is a potent LRRK2 PROTAC degrader with anti-neuroinflammatory activity .
    Azacyclohexane-O-cyclohexane-C-(OCH3)2
  • HY-179071
    DAPK1 ligand-1

    		Target Protein Ligand-Linker Conjugates DAPK Neurological Disease
    DAPK1 ligand-1 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC DAPK1 Degrader-1 (HY-179055). PROTAC DAPK1 Degrader-1 is a potent LAG-3 PROTAC degrader with neuroprotective activity .
    DAPK1 ligand-1
  • HY-175549
    HPK1 ligand 4

    		Ligands for Target Protein for PROTAC MAP4K Cancer
    HPK1 ligand 4 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC HPK1 Degrader-5 (HY-175547). PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader with anti-tumor activity .
    HPK1 ligand 4
  • HY-155582
    BLK degrader 1

    		Src Cancer
    BLK degrader 1 (compound 9) is a selective degrader of B-lymphoid tyrosine kinase (BLK). BLK degrader 1 shows anticancer activity in several B-lymphoid cell lines .
    BLK degrader 1
  • HY-162679
    c-Met degrader-1

    		c-Met/HGFR Apoptosis Cancer
    c-Met degrader-1 (Compound H11) is an orally active c-Met degrader (through the ubiquitin proteasome system). c-Met degrader-1 has anti-hepatocellular carcinoma activity (HCC) and inhibits tumor growth in MHCC97H xenografts. c-Met degrader-1 inhibits HCC cell growth, arrests cell cycle, and induces apoptosis. c-Met degrader-1 may overcome resistance to type Ib inhibitors .
    c-Met degrader-1
  • HY-177728
    MG degrader 3

    		Molecular Glues Cancer
    MG degrader 3 is a molecular glucose degrading agent that targets the CRBN protein. MG degrader 3 has certain anti proliferative activity in MM.1S cells (IC50 = 8.7 nM). MG degrader 3 can be used for cancer research .
    MG degrader 3
  • HY-128841
    PROTAC MDM2 Degrader-2
    1 Publications Verification

    		 PROTACs MDM-2/p53 E1/E2/E3 Enzyme Cancer
    PROTAC MDM2 Degrader-2 is an MDM2 PROTAC degrader. PROTAC MDM2 Degrader-2 can induce the self-ubiquitination and degradation of MDM2, thereby upregulating the level of p53 protein. PROTAC MDM2 Degrader-2 has anti-tumor activity and can be used in the study of cancer . (Blue: MDM2 ligand (HY-128836); Black: linker (HY-128833))
    PROTAC MDM2 Degrader-2
  • HY-153864
    PROTAC MEK1 Degrader-1

    		PROTACs MEK ERK Cancer
    PROTAC MEK1 Degrader-1 is a PROTAC targeting MEK1 with a pIC50 value of 7.0. PROTAC MEK1 Degrader-1 consists of a MEK1 inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit ERK1/2 phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells .
    PROTAC MEK1 Degrader-1
  • HY-175337
    c-Met ligand-Linker Conjugate 2

    		Target Protein Ligand-Linker Conjugates c-Met/HGFR Cancer
    c-Met ligand-Linker Conjugate 2 is a synthesized target protein ligand-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC c-Met degrader-6 (HY-175321). PROTAC c-Met degrader-6 is a c-Met PROTAC degrader with anti-tumor activity [1] .
    c-Met ligand-Linker Conjugate 2
  • HY-178888
    Nrf2 ligand-Linker Conjugate 2

    		PROTAC-Linker Conjugates for PAC Cancer
    Nrf2 ligand-Linker Conjugate 2 is a synthesized Nrf2 ligand-linker conjugate that can be used for synthesis of PROTAC K-Ras Degrader-7 (HY-178873). PROTAC K-Ras Degrader-7 is a potent K-Ras PROTAC degrader with anti-tumor activity .
    Nrf2 ligand-Linker Conjugate 2
  • HY-152227
    PROTAC TYK2 degradation agent1

    		PROTACs JAK Inflammation/Immunology
    PROTAC TYK2 degradation agent1 is a potent and subtype-selective TYK2 degrader. PROTAC TYK2 degradation agent1 has TYK2 degradation activity with DC50 value of 14 nM. PROTAC TYK2 degradation agent1 can be used for the research of autoimmune disease .
    PROTAC TYK2 degradation agent1
  • HY-157804
    PROTAC SARS-CoV-2 Mpro degrader-1

    		PROTACs SARS-CoV Infection
    PROTAC SARS-CoV-2 Mpro degrader-1 (compound 5) is a PROTAC degrader targeting the major SARS-CoV-2 protease with broad-spectrum antiviral activity .
    PROTAC SARS-CoV-2 Mpro degrader-1
  • HY-174138
    NF-κB degrader 1

    		NF-κB Inflammation/Immunology
    NF-κB degrader 1 (Compound MD-1) is a NF-κB1 p105 subunit degrader. NF-κB degrader 1 shows anti-inflammatory activity (IC50 for inhibiting TNF-α is 2.02 μM, and for inhibiting NO is 5.40 μM). NF-κB degrader 1 induces p105 degradation dependent on the Cullin-RING ligase (CRL) SCFBTCP, suppressing NF-κB transcriptional activity. NF-κB degrader 1 is promising for research of inflammation-related diseases .
    NF-κB degrader 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: